Bruker (BRKR) came out with quarterly earnings of $0.52 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this scientific equipment maker would post earnings of $0.46 per share when it actually produced earnings of $0.53, delivering a surprise of 15.22%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Bruker, which be ...

Exhibit 99.1 Bruker Reports Second Quarter 2024 Financial Results • Q2 2024 revenues of $800.7 million, up 17.4% year-over-year (yoy); organic revenue up 7.4% yoy; CER revenue up 18.5% yoy • Q2 2024 GAAP EPS $0.05; non-GAAP EPS $0.52, up 4.0% yoy • Bruker increases FY 2024 revenue guidance to $3.38-$3.44 billion, now including the NanoString business; implies revenue growth of 14% to 16%, and organic revenue growth of 5% to 7% yoy BILLERICA, Massachusetts – August 6, 2024 – Bruker Corporation (Nasdaq: BRKR) ...

For Immediate Release Chicago, IL – August 6, 2024 – Today, Zacks Equity Research discusses Mettler-Toledo International (MTD) and Bruker (BRKR) . Industry: Instruments – Scientific Link: https://www.zacks.com/commentary/2316245/2-instruments-stocks-to-watch-from-a-prospering-industry 2 Instruments Stocks to Watch From a Prospering Industry The Zacks Instruments - Scientific industry is benefiting from increasing healthcare spending, driven by aging demography, and continued innovation in the pharma and lif ...

The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. Zacks Consensus Estimate Revenues are expected to be $796.23 million, up 16.8% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Earnings Whisper The Zacks ...

Bruker's (BRKR) strong growth reflects its fundamental commitment to innovate high-value solutions and the ongoing portfolio transformation. Yet, the company's operations bear the brunt of excessive currency exposure and general macroeconomic headwinds. The stock carries a Zacks Rank #3 (Hold) at present. The CALID segment has been gaining from the strong demand for differentiated instruments, particularly life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments ...

Hims & Hers Heath stock has surged 181.7% in the past year. Estimates for the company's earnings have increased from 18 cents to 19 cents for 2024 and from 33 cents to 35 cents for 2025 in the past 30 days. On the flip side, Bruker generates a substantial portion of its revenues in the international markets, primarily in Germany and other countries in the European Union, Switzerland and Japan. As a result, currency fluctuations continue to result in foreign currency transaction losses at the company. In add ...

Industry Overview - The global nanotech market was valued at $3.69 billion in 2022 and is projected to reach $36.85 billion by 2030, representing a compound annual growth rate (CAGR) of 33.1% [2] - Nanotechnology focuses on manipulating atoms and molecules at the nanoscale, with applications across various scientific domains including chemistry, biomedical science, mechanics, and materials science [4][11] Company Analysis: Veeco Instruments (VECO) - Veeco Instruments has shown robust performance in 2023, with an average earnings per share (EPS) of 46.3 cents and an earnings surprise of 23.6% from Q2 2023 to Q1 2024 [3] - Despite a net loss of $17.25 million over the trailing 12 months, Veeco's revenue reached $687.41 million, with analysts predicting a recovery in fiscal 2024, expecting EPS to rise by 7.1% to $1.81 and sales to increase by 8% to $719.47 million [5] Company Analysis: Bruker (BRKR) - Bruker has demonstrated consistent financial performance, with an average EPS of 64.3 cents and an earnings surprise of 13.63% from Q2 2023 to Q1 2024 [6] - For fiscal 2025, EPS is expected to increase by 18% to $3.14, while revenue may rise by 8.6% to reach $3.67 billion [7] Company Analysis: Luna Innovations (LUNA) - Luna Innovations is characterized by its speculative nature, with a net loss of $1.12 million and revenue of $116.61 million during the trailing 12 months [19] - Analysts project fiscal 2024 revenue to rise to $165.24 million, indicating a significant potential for growth despite its high-risk profile [9]

Bruker Corporation (BRKR) recently announced the launch of the neofleX Imaging Profiler for mass spectrometry-based tissue imaging at the 72nd ASMS meeting. The novel, high-performance MALDITOF/TOF system enables facile OME-TIFF file output via the new SCiLS Scope software and conveniently fits on a benchtop. The latest development is expected to significantly boost the company's Life Sciences Mass Spectrometry division within the Bruker Scientific Instruments ("BSI") CALID segment. About neofleX The neofle ...

Core Insights - Biognosys will showcase its advancements in mass spectrometry-based proteomics at the ASMS Annual Conference, including the launch of Spectronaut 19 and other innovative solutions [1][2] Group 1: Product Launches and Features - Spectronaut 19 introduces significant improvements in peptide and protein identification, candidate discovery rates, scalability for large-scale analysis, and support for novel workflows [3][6] - The new P2 Plasma Enrichment method enhances the TrueDiscovery platform, offering superior performance for deep plasma proteomics and is available as a CRO service or in-house method [5][6] - TrueTarget® platform features a high-throughput LiP-MS workflow for efficient drug target deconvolution screening, improving target identification and reducing measurement time [8][6] Group 2: Scientific Presentations and Engagements - Biognosys will host two breakfast seminars, four oral presentations, and eleven posters at the ASMS conference, highlighting the capabilities of Spectronaut 19 and other technologies [2][4] - Key presentations include topics on quantitative proteomics and high-dimensional phosphoproteomics, showcasing the software's application in various research areas [4][7] Group 3: Data Insights Solutions - DigitalProteome™ database provides insights into protein expression and supports biomarker discovery, featuring profiles from 22 healthy tissues and available for biopharma research [9][10] - Proteoverse™ platform allows for data visualization and exploration, enabling users to extract biological insights and examine peptide-level structures [10][9]

Bruker Corporation's (BRKR) strong growth reflects its fundamental commitment to innovate high-value solutions, and the ongoing portfolio transformation. However, macroeconomic issues dent profit. The stock carries a Zacks Rank #3 (Hold) currently. Bruker's CALID business has been gaining from the strong demand for differentiated instruments, particularly in life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments. Bruker's flagship timsTOF platform is a key dri ...